| Literature DB >> 24267671 |
Niklaus Daniel Labhardt1, Olivia Keiser, Motlalepula Sello, Thabo Ishmael Lejone, Karolin Pfeiffer, Mary-Ann Davies, Matthias Egger, Jochen Ehmer, Gilles Wandeler.
Abstract
INTRODUCTION: Lesotho was among the first countries to adopt decentralization of care from hospitals to nurse-led health centres (HCs) to scale up the provision of antiretroviral therapy (ART). We compared outcomes between patients who started ART at HCs and hospitals in two rural catchment areas in Lesotho.Entities:
Keywords: HIV; antiretroviral treatment; decentralization; nurse-based care; retention in care; rural Southern Africa; task shifting
Mesh:
Substances:
Year: 2013 PMID: 24267671 PMCID: PMC3838571 DOI: 10.7448/IAS.16.1.18616
Source DB: PubMed Journal: J Int AIDS Soc ISSN: 1758-2652 Impact factor: 5.396
Resources available for ART services at the two hospitals and the 12 health centres involved in the study
| Seboche | Paray | |||
|---|---|---|---|---|
|
|
| |||
| Hospital ( | Health centres ( | Hospital ( | Health centres ( | |
| Number of physicians | 4 | 0 | 4 | 0 |
| Number of nurse-clinicians per facility providing ART | 3 | 1 | 2 | 1 |
| Number of nurse-assistants per facility involved in ART | 2 | 1 | 3 | 1 |
| Number of lay counsellors per facility | 5 | 2 | 7 | 2 |
| Number of new adult patients enrolled in ART per facility from 1 January 2008 to 30 April 2011 | 873 | 159 | 832 | 178 |
| Nurse-clinician/patient ratio | 1/291 | 1/159 | 1/419 | 1/178 |
| CD4 testing on site | Yes | No | Yes | No |
| Haemoglobin testing on site | Yes | 2 out of 5 | Yes | 2 out of 7 |
| Biochemistry on site | Yes | No | Yes | No |
| Viral load testing on site | No | No | No | No |
| TB services available | Yes | Yes | Yes | Yes |
| Sputum microscopy on site | Yes | No | Yes | No |
| X-ray on site | Yes | No | Yes | No |
Figure 1Flow chart of patients starting antiretroviral therapy (ART) in health centres (HCs) and hospitals (flow charts stratified by gender are displayed in the Supplementary file). LTFU: Lost to follow-up
Baseline characteristics of patients starting ART in hospitals and health centres (HCs), stratified by gender (see Web-Table 1 for stratification by catchment area)
| Female patients ( | Male patients ( | ||||||
|---|---|---|---|---|---|---|---|
|
|
| ||||||
| Hospital | HC |
| Hospital | HC |
| Total | |
| Number of patients | 1086 | 1309 | 619 | 733 | 3747 | ||
| Median age in years (IQR) | 35 (30–45) | 39 (33–49) | 0.021 | 37 (30–48) | 42 (35–50) | 0.017 | 38 (31–48) |
| Median CD4 cell count/µl (IQR) | 183 (86–281) | 223 (142–296) | <0.001 | 138 (60–233) | 196 (102–276) | <0.001 | 194 (102–281) |
| CD4 categories (cells/µl) (%) | <0.001 | <0.001 | |||||
| 0–49 | 137 (12.6) | 77 (5.9) | 117 (18.9) | 87 (11.9) | 418 (11.2) | ||
| 50–99 | 163 (15.0) | 100 (7.6) | 112 (18.1) | 83 (11.3) | 458 (12.2) | ||
| 100–199 | 267 (42.6) | 368 (28.1) | 169 (27.3) | 191 (26.1) | 995 (26.6) | ||
| ≥ 200 | 486 (44.8) | 730 (55.8) | 197 (31.8) | 344 (46.9) | 1757 (46.9) | ||
| Missing | 33 (3.0) | 34 (2.6) | 24 (3.9) | 28 (3.8) | 119 (3.2) | ||
| Median haemoglobin (g/dl) | 11.3 (10.0–12.6) | 12 (11.0–13.0) | <0.001 | 12.4 (10.8–14.0) | 12.9 (11.5–14.7) | 0.004 | 11.9 (10.6–13.2) |
| Missing haemoglobin (%) | 422 (38.9) | 889 (67.9) | <0.001 | 272 (43.9) | 513 (69.9) | <0.001 | 2096 (55.9) |
| WHO stage (%) | <0.001 | <0.001 | |||||
| I/II | 607 (55.9) | 959 (73.4) | 242 (39.1) | 426 (58.2) | 2234 (59.7) | ||
| III/IV | 479 (44.1) | 348 (26.6) | 377 (60.9) | 306 (41.8) | 1510 (40.3) | ||
| NNRTI | 0.003 | 0.044 | |||||
| NVP based (%) | 421 (38.8) | 589 (45.0) | 126 (20.4) | 184 (25.1) | 1320 (35.2) | ||
| EFV based (%) | 658 (60.6) | 416 (54.7) | 488 (78.8) | 547 (74.6) | 2409 (64.6) | ||
| NRTI | |||||||
| 3TC/D4T (%) | 175 (16.1) | 312 (23.8) | <0.001 | 82 (13.3) | 181 (24.6) | <0.001 | 749 (19.9) |
| 3TC/AZT (%) | 339 (31.2) | 526 (40.2) | <0.001 | 156 (25.2) | 179 (24.4) | 0.740 | 1198 (31.9) |
| 3TC/TDF (%) | 567 (52.2) | 469 (35.8) | <0.001 | 381 (61.6) | 371 (50.6) | <0.001 | 1782 (47.6) |
IQR: interquartile range; NNRTI: non-nucleoside reverse-transcriptase inhibitor; NtRTI: nucleoside analogue reverse-transcriptase inhibitor; 3TC: lamivudine; D4T: stavudine; AZT: zidovudine; TDF: tenofovir.
Figure 2Retention in care over three years, stratified by type of facility (A: female; B: male).
Health centres versus hospitals: adjusted outcomes by gender (hospitals are the reference)
| Overall | Male | Female | |
|---|---|---|---|
| Retention | 1.10 (0.94–1.28) | 1.53 (1.20–1.96) | 0.89 (0.73–1.09) |
| No follow-up | 0.62 (0.39–0.98) | 0.67 (0.31–1.43) | 0.60 (0.34–1.07) |
| Mortality | 0.98 (0.80–1.19) | 0.79 (0.59–1.06) | 1.19 (0.91–1.57) |
| LTFU | 0.98 (0.82–1.18) | 0.68 (0.51–0.93) | 1.21 (0.95–1.51) |
The estimates are ORs for retention and no FUP, and sub-distribution hazard ratios from competing risk regression for mortality and LTFU. Analyses are adjusted for age, baseline CD4 cell count, clinical WHO stage, type of NNRTI and catchment area. LTFU: Lost to follow-up.